Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : DNDN - Dendreon Corp. -- Ignore unavailable to you. Want to Upgrade?

To: Elmer who wrote (58)	10/11/2000 11:36:05 AM
From: brk	Respond to of 751

Dendreon Announces Collaboration with The R.W. Johnson Pharmaceutical Research Institute in Development of Immunotherapy for Cancer Business Editors/Health & Medical Writers SEATTLE--(BW HealthWire)--Oct. 11, 2000-- leader in cancer vaccines to advance research and development activities Dendreon Corporation (Nasdaq:DNDN) today announced the signing of a strategic collaboration agreement for the advancement of cancer immunotherapies with The R.W. Johnson Pharmaceutical Research Institute (PRI), a member of the Johnson & Johnson family of companies (NYSE:JNJ). The collaboration will provide the opportunity for Dendreon and PRI to use each other's products and technologies to develop optimal immunotherapies, including dendritic cell-based vaccine therapy for the treatment of a variety of cancers, including breast, ovarian and colorectal cancers. The collaboration will also involve the use of products and technologies that may be developed by the companies. "PRI is a strong partner for Dendreon Corporation," said David Urdal, Ph.D., Chief Scientific Officer of Dendreon. "PRI's innovation in biotechnology, coupled with Dendreon's leadership in the cancer immunotherapy arena, provides a significant validation for this important area of clinical development and a strong groundwork for our future research and development activities." Under the terms of the agreement, PRI will provide financial support for research and development activities to be carried out by Dendreon. Dendreon will also be responsible for clinical testing. Immunotherapy treatments aim to harness the natural power of the immune system to fight against diseases such as cancer. Avoiding the harsh side effects associated with other forms of treatment, immunotherapies may offer new hope to patients. Dendreon Corporation (www.dendreon.com) is dedicated to the discovery and development of novel products for the treatment of cancer through its innovative manipulation of the immune system. Dendreon is focused on the development of therapeutic cancer vaccines through the use of antigen discovery, antigen engineering and dendritic cell technologies. Dendreon's vaccine for the treatment of prostate cancer, Provenge(TM), is in Phase III clinical trials and its vaccine for the treatment of multiple myeloma, Mylovenge(TM), is in Phase II clinical trials. Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties that may cause actual results to differ materially from the results discussed in the forward-looking statements, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such a difference include risks related to Dendreon's limited operating history, risks associated with completing our clinical trials, and dependence on the efforts of third parties, and our dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations, are contained in Dendreon's SEC Reports, including Dendreon's Form 10-Q and Form S-1 Registration Statement, No. 333-31920, which are available at www.sec.gov. --30--AMP/se* CONTACT: Dendreon Corporation Julie Rathbun, 206/256-4545 ext. 1500 jrathbun@dendreon.com

To: Elmer who wrote (58)	10/11/2000 11:37:20 AM
From: brk	Read Replies (2) \| Respond to of 751

I don't know if I like this...... Dendreon Corporation Files Registration Statement for the Public Offering of 2,500,000 Shares of Common Stock Business Editors/Health & Medical Writers SEATTLE--(BW HealthWire)--Oct. 11, 2000--Dendreon Corporation (Nasdaq:DNDN) today announced that it has filed with the Securities and Exchange Commission a registration statement relating to a proposed public offering of 2,500,000 shares of common stock. The offering will be lead-managed by Prudential Vector Healthcare Group, a unit of Prudential Securities Incorporated, and co-managed by SG Cowen Securities Corporation and Pacific Growth Equities, Inc. Dendreon, based in Seattle, Washington, is dedicated to the discovery and development of novel products for the treatment of cancer through its innovative manipulation of the immune system. Dendreon is focused on the development of novel therapeutic vaccines for the treatment of cancer using proprietary antigen discovery, antigen engineering and dendritic cell technologies, including a prostate cancer vaccine, Provenge(TM), which is in Phase III clinical trials, and a therapeutic vaccines for B-cell malignancies, Mylovenge(TM), which is in Phase II trials. A copy of the preliminary prospectus relating to these securities may be obtained, when available, from Prudential Securities, 111 8th Avenue, 5th Floor, New York, New York 10011, phone: 212/776-8172, fax: 212/776-8144. A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under securities laws or any such state or jurisdiction. --30--AMP/se* CONTACT: Dendreon Corporation Martin Simonetti, 206/256-4545 ext. 1500 pr@dendreon.com